Abzena announces licensing agreement for T-cell engineering

By Maggie Lynch

- Last updated on GMT

(Image: Getty/scyther5)
(Image: Getty/scyther5)

Related tags CAR-T Cell biology Antibody Antibody drug conjugates

Abzena has signed an antibody humanization agreement with Tmunity Therapeutics a clinical stage T cell therapy company.

Per the agreement, the technology and services provider Abzena will humanize monoclonal antibodies using its Composite Human Antibody technology (CHA). CHA combines humanization and deimmunisation technologies to create therapeutic antibodies without CD4+ T cell epitopes​.

John Burt CEO of Abzena told us, “The licensing agreement arises through Tmunity’s access to Abzena’s composite human antibody technology to create humanized CAR [​Chimeric Antigen Receptor] sequences.”

Abzena will be paid milestone payments if any products containing the humanized antibody sequences reach investigational new drug (IND) acceptance.

CAR-T therapy is a form of precision medicine that uses an individual’s genetically modified cells as a way of killing cancer cells. It has been developed for the treatment of hematological cancers. 

“The Composite Human Antibody Technology removes putative T cell epitope sequences from antibody sequences to reduce the risk of immunogenicity of these products on administration to patients,”​ said Burt.

The license agreement also includes a developability assessment for Tumunity to assess any sequence liabilities that would impact the product and EpiScreen, Abzena’s ex-vivo immunogenicity assessment platform. 

Related topics Preclinical

Related news

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more